Oligometastatic Disease - Epidemiology Forecast - 2032

Key Highlights

• The oligometastatic disease is characterized by limited metastatic spread, typically involving one to five distant sites beyond the primary tumor.
• Even among cancer researchers, the oligometastatic concept is not always well understood. The most important idea is that metastasis is a spectrum, both in the number of tumors and the speed at which the disease spreads.
• No agreed-upon number of metastases delineates oligometastatic cancer from more widespread disease. Many studies have drawn the line at five, but that number was “arbitrarily decided upon.” Part of the confusion is that oligometastatic cancer has no precise definition.
• The term oligometastatic disease (OMD) was introduced into the clinical practice almost 30 years ago to delineate a patient group with few distant metastases that could benefit from a curative therapeutic strategy employing a local approach.
• The concept challenges the traditional view of cancer as a uniformly progressive and systemic disease, suggesting that some patients may benefit from aggressive local treatment to control or eradicate metastatic lesions.
• The accurate diagnosis of the oligometastatic disease relies on advanced imaging techniques, such as positron emission tomography-computed tomography (PET-CT) and magnetic resonance imaging (MRI), to identify and localize metastatic lesions.
• In 2022, there were ~325,000 oligometastatic disease cases in the 7MM.
• In 2022, the highest number of oligometastatic were observed in non-small cell lung cancer, with ~27,000 cases, followed by colorectal cancer, with ~22,000 cases, in Japan.
• The United States accounted ~27,000 cases, ~86,000 cases, ~3,000 cases for synchronous, metachronous, and unknown types in 2022.
• EU4 and the UK accounted for ~40,000 oligorecurrent cases. Among EU4 and the UK, Germany accounted for the highest number of oligorecurrent cases.
• In 2022, Spain accounted for the lowest number of oligoreccurent cases out of all the 7MM countries accounting for around 6% of the total cases in the 7MM.

This “Oligometastatic Disease - Epidemiology Forecast - 2032” report delivers an in-depth understanding of the oligometastatic disease, historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Geography Covered

• The United States
• EU4 (Germany, France, Italy, and Spain) and the United Kingdom
• Japan

Study Period: 2019-2032

Oligometastatic Disease Understanding and Diagnostic Algorithm

Oligometastatic Disease Overview

The oligometastatic disease is a distinct state in cancer patients, characterized by limited metastatic spread, typically involving one to five distant sites beyond the primary tumor. There is no consensus on the definition of oligometastatic cancer, but no more than five radiologically visible metastases are considered a reasonable benchmark, which has also been used as a standard by the recently published ASTRO-ESTRO's clinical practice guideline for oligometastatic non-small cell lung cancer.

The oligometastatic disease is primarily subclassified into synchronous or metachronous, where synchronous patients are those that are initially diagnosed with oligometastasis, while metachronous patients are those patients that present with oligometastasis after treatment of the primary tumor. Metachronous patients are further subclassified into oligorecurrent, oligoprogressive, and oligopersistent, based on patient prognosis after primary tumor treatment.

Oligometastatic Disease Diagnosis

The accurate diagnosis of the oligometastatic disease relies on advanced imaging techniques, such as positron emission tomography-computed tomography (PET-CT) and magnetic resonance imaging (MRI), to identify and localize metastatic lesions.

Further details related to diagnosis are provided in the report…

Oligometastatic Disease Epidemiology

As the market is derived using a patient-based model, the oligometastatic disease epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by total oligometastatic disease cases, oligometastatic disease cases by major cancer indications, type-specific cases of oligometastatic disease, total oligorecurrent cases, and oligorecurrent cases by major cancer indications in the 7MM covering the United States, EU4 countries (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2019 to 2032.

• In the United States, non-small cell lung cancer patients are estimated to have accounted for the largest share of oligometastatic cases, accounting for ~46,000 cases of oligometastatic non-small cell lung cancer.
• Among EU4 countries and the UK, Germany had the highest number of oligometastatic disease cases, with ~36,000 cases in 2022. On the other hand, Spain had the lowest number of oligometastatic disease cases, with ~19,000 cases in 2022.
• In Japan, the total cases of the oligometastatic disease were estimated to be ~71,000 in 2022.

Scope of the Report

• The report covers a segment of an executive summary and a descriptive overview of oligometastatic disease, explaining related terminologies, major types of cancers with oligometastatic, and diagnosis.
• Comprehensive insight into the country-wise epidemiology segments and forecasts, the future growth potential of cases, and insights on disease progression have been provided.
• Patient stratification based on oligometastasis in major types of cancers, type of oligometastasis, and oligorecurrence, is an inclusion.
• A detailed review of current challenges in establishing the diagnosis.

Oligometastatic Disease Report Insights

• Oligometastatic Disease Patient Population
• Oligometastasis in Major Types of Cancers
• Type-specific Oligometastatic Cases
• Oligorecurrence Cases
• Oligorecurrence in Major Types of Cancers
• Country-wise Epidemiology Distribution

Oligometastatic Disease Report Key Strengths

• Ten years Forecast
• The 7MM Coverage
• Oligometastatic Disease Epidemiology Segmentation

Oligometastatic Disease Report Assessment

• Epidemiology Segmentation
• Current Diagnostic Practices

Key Questions Answered

Epidemiology Insights

• What are the biological basis, major types, and unmet needs of oligometastatic disease? What will be the growth opportunities across the 7MM with respect to the patient population of oligometastatic disease?
• What is the historical and forecasted oligometastatic disease patient pool in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan?
• Which cancer type shows the maximum oligorecurrence in the 7MM?
• Which type of oligometastatic disease has the most cases in the 7MM?
• What factors are affecting the increase in the diagnosis rate of oligometastatic disease?

Reasons to Buy

• Insights on patient burden/disease numbers, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
• To understand the change in oligometastatic disease cases in varying geographies over the coming years.
• A detailed overview of oligometastasis in major cancer types, type-specific, and oligorecurrence in major cancer types is included.
• Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.